SS Innovations International, Inc. — Form 8-K
Filed September 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
As of September 8, 2026, SS Innovations reported 238 cumulative SSi Mantra installations (up 42% from 168 at end-2025) spanning 12 countries, with 14,103 total procedures completed (up 79% from 7,885 in 2025). Key milestones include first robotic cardiac surgery in Colombia (July 29), first system installation in Sri Lanka (August 23), 258 cumulative pediatric surgeries, 188 telesurgeries, and 50 procedures in a single day at one facility. FDA 510(k) review expected by Q1 2027; EU CE marking targeted by end-2026.
Why this rating
Strong operational growth (42% installations, 79% procedures) is material progress but pre-revenue/pre-regulatory approval stage limits current impact relative to $270M market cap. Near-term catalysts are regulatory approvals, not yet realized.
See more from September 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.